Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Analysts
      • Trading information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Renumeration

Press releases

All press releases Regulatory

Regulatory press release 2023-02-23

Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

Regulatory press release 2023-02-15

Interim Report Fourth Quarter 2022

Regulatory press release 2022-11-09

Interim Report Third Quarter 2022

Regulatory press release 2022-10-31

Number of shares and votes in Xspray Pharma

Regulatory press release 2022-10-25

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023

Regulatory press release 2022-10-17

Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100

Regulatory press release 2022-08-05

Interim Report Second Quarter 2022

Regulatory press release 2022-06-17

Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia

Regulatory press release 2022-06-15

Xspray Pharma appoints Thomas Walz as Chief Medical Officer

Regulatory press release 2022-05-19

Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)

Show more

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.

IR contact

Kerstin Hasselgren, Chief Financial Officer

+46 (0)70 311 16 83

info@xspray.com

Xspray-logo-white

Xspray Pharma AB Råsundavägen 12 169 67 Solna

+46 (0)8 730 37 00 info@xspraypharma.com